These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26534939)

  • 1. PDGFR Inhibition Results in Pericyte Depletion and Hemorrhage into the Corpus Luteum of the Rat Ovary.
    Hall AP; Ashton S; Horner J; Wilson Z; Reens J; Richmond GH; Barry ST; Wedge SR
    Toxicol Pathol; 2016 Jan; 44(1):98-111. PubMed ID: 26534939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent.
    Pauli SA; Tang H; Wang J; Bohlen P; Posser R; Hartman T; Sauer MV; Kitajewski J; Zimmermann RC
    Endocrinology; 2005 Mar; 146(3):1301-11. PubMed ID: 15591152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis.
    Kuhnert F; Tam BY; Sennino B; Gray JT; Yuan J; Jocson A; Nayak NR; Mulligan RC; McDonald DM; Kuo CJ
    Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10185-90. PubMed ID: 18632559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
    Erber R; Thurnher A; Katsen AD; Groth G; Kerger H; Hammes HP; Menger MD; Ullrich A; Vajkoczy P
    FASEB J; 2004 Feb; 18(2):338-40. PubMed ID: 14657001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
    Hasumi Y; Kłosowska-Wardega A; Furuhashi M; Ostman A; Heldin CH; Hellberg C
    Int J Cancer; 2007 Dec; 121(12):2606-14. PubMed ID: 17691110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea.
    Zimmermann RC; Hartman T; Bohlen P; Sauer MV; Kitajewski J
    Microvasc Res; 2001 Jul; 62(1):15-25. PubMed ID: 11421657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of corpus luteum angiogenesis in immature hypothyroid rdw rats after thyroxine treatment: morphologic and molecular evidence.
    Macchiarelli G; Palmerini MG; Nottola SA; Cecconi S; Tanemura K; Sato E
    Theriogenology; 2013 Jan; 79(1):116-26. PubMed ID: 23122683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-derived growth factors and receptors in the rat corpus luteum: localization and identification of an effect on luteogenesis.
    Sleer LS; Taylor CC
    Biol Reprod; 2007 Mar; 76(3):391-400. PubMed ID: 17108335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian vascular endothelial growth factor and vascular endothelial growth factor receptor patterns in reproductive aging.
    Yeh J; Kim BS; Peresie J
    Fertil Steril; 2008 May; 89(5 Suppl):1546-56. PubMed ID: 17889862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular composition, apoptosis, and expression of angiogenic factors in the corpus luteum during prostaglandin F2alpha-induced regression in sheep.
    Vonnahme KA; Redmer DA; Borowczyk E; Bilski JJ; Luther JS; Johnson ML; Reynolds LP; Grazul-Bilska AT
    Reproduction; 2006 Jun; 131(6):1115-26. PubMed ID: 16735551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis.
    Goede V; Schmidt T; Kimmina S; Kozian D; Augustin HG
    Lab Invest; 1998 Nov; 78(11):1385-94. PubMed ID: 9840613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
    Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
    Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis in the human corpus luteum: changes in expression of angiopoietins in the corpus luteum throughout the menstrual cycle and in early pregnancy.
    Sugino N; Suzuki T; Sakata A; Miwa I; Asada H; Taketani T; Yamagata Y; Tamura H
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6141-8. PubMed ID: 16118339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular morphogenesis in the ovary.
    Augustin HG
    Baillieres Best Pract Res Clin Obstet Gynaecol; 2000 Dec; 14(6):867-82. PubMed ID: 11141338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular dynamics in relation to immunolocalisation of VEGF-A, VEGFR-2 and Ang-2 in the bovine corpus luteum.
    Hünigen H; Bisplinghoff P; Plendl J; Bahramsoltani M
    Acta Histochem; 2008; 110(6):462-72. PubMed ID: 18541291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
    Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
    Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hypo- and hyperthyroidism on proliferation, angiogenesis, apoptosis and expression of COX-2 in the corpus luteum of female rats.
    Silva JF; Ocarino NM; Vieira AL; Nascimento EF; Serakides R
    Reprod Domest Anim; 2013 Aug; 48(4):691-8. PubMed ID: 23369109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shb promotes blood vessel formation in embryoid bodies by augmenting vascular endothelial growth factor receptor-2 and platelet-derived growth factor receptor-beta signaling.
    Rolny C; Lu L; Agren N; Nilsson I; Roe C; Webb GC; Welsh M
    Exp Cell Res; 2005 Aug; 308(2):381-93. PubMed ID: 15919073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
    Mancuso MR; Davis R; Norberg SM; O'Brien S; Sennino B; Nakahara T; Yao VJ; Inai T; Brooks P; Freimark B; Shalinsky DR; Hu-Lowe DD; McDonald DM
    J Clin Invest; 2006 Oct; 116(10):2610-21. PubMed ID: 17016557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.